Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

High-risk human papillomavirus seems not involved in DES-related and of limited importance in nonDES related clear-cell carcinoma of the cervix.

Kocken M, Baalbergen A, Snijders PJ, Bulten J, Quint WG, Smedts F, Meijer CJ, Helmerhorst TJ.

Gynecol Oncol. 2011 Aug;122(2):297-302. doi: 10.1016/j.ygyno.2011.05.002.

PMID:
21620450
2.

Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix.

Waggoner SE, Anderson SM, Van Eyck S, Fuller J, Luce MC, Herbst AL.

Obstet Gynecol. 1994 Sep;84(3):404-8.

PMID:
8058239
3.

Clear cell adenocarcinoma of the vagina and cervix. An update of the central Netherlands registry showing twin age incidence peaks.

Hanselaar A, van Loosbroek M, Schuurbiers O, Helmerhorst T, Bulten J, Bernhelm J.

Cancer. 1997 Jun 1;79(11):2229-36.

PMID:
9179071
4.

Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero.

Boyd J, Takahashi H, Waggoner SE, Jones LA, Hajek RA, Wharton JT, Liu FS, Fujino T, Barrett JC, McLachlan JA.

Cancer. 1996 Feb 1;77(3):507-13.

5.

The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix.

Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ.

J Pathol. 2003 Dec;201(4):535-43.

PMID:
14648656
6.

[Vaginal and cervical cancer due to diethylstilbestrol (DES); end epidemic].

van Dijck JA, Doorduijn Y, Bulten JH, Verloop J, Massuger LF, Kiemeney BA.

Ned Tijdschr Geneeskd. 2009;153:A366. Dutch.

PMID:
19857300
7.

The current status of the DES-exposed population.

Herbst AL.

Obstet Gynecol Annu. 1981;10:267-78. Review.

PMID:
7024873
8.
9.

Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix.

Herbst AL, Cole P, Colton T, Robboy SJ, Scully RE.

Am J Obstet Gynecol. 1977 May 1;128(1):43-50.

PMID:
851158
10.

Management of the adolescent girl exposed in utero to DES.

Gerbie MV.

Pediatr Ann. 1981 Dec;10(12):23-6.

PMID:
7335401
12.
13.

Clear cell adenocarcinoma of the vagina and cervix: incidence, undetected disease, and diethylstilbestrol.

Horwitz RI, Viscoli CM, Merino M, Brennan TA, Flannery JT, Robboy SJ.

J Clin Epidemiol. 1988;41(6):593-7.

PMID:
3385459
14.

Intrauterine exposure to diethylstilbestrol: long-term effects in humans.

Swan SH.

APMIS. 2000 Dec;108(12):793-804. Review.

PMID:
11252812
15.

Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol.

Bornstein J, Adam E, Adler-Storthz K, Kaufman RH.

Obstet Gynecol Surv. 1988 Jan;43(1):15-21. Review.

PMID:
2829071
16.

Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update.

Melnick S, Cole P, Anderson D, Herbst A.

N Engl J Med. 1987 Feb 26;316(9):514-6.

PMID:
3807995
17.
18.

Findings in female offspring of women exposed in utero to diethylstilbestrol.

Kaufman RH, Adam E.

Obstet Gynecol. 2002 Feb;99(2):197-200.

PMID:
11814496
19.
20.

DES daughters in France: experts' points of view on the various genital, uterine and obstetric pathologies, and in utero DES exposure.

Clement R, Guilbaud E, Barrios L, Rougé-Maillart C, Jousset N, Rodat O.

Med Sci Law. 2014 Oct;54(4):219-29. doi: 10.1177/0025802414523266.

PMID:
24534146
Items per page

Supplemental Content

Support Center